PP
ARCT icon

PDT Partners’s Arcturus Therapeutics ARCT Stock Holding History

PDT Partners’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-90,298
Closed -$1.53M – 740
2024
Q4 		$1.53M Buy
90,298
+15,154
+20% +$285K 0.14% 256
2024
Q3 		$1.74M Buy
+75,144
New +$1.61M 0.15% 243
2022
Q3 		– Sell
-74,636
Closed -$1.18M – 836
2022
Q2 		$1.18M Buy
74,636
+25,136
+51% +$493K 0.1% 342
2022
Q1 		$1.33M Sell
49,500
-3,523
-7% -$89.9K 0.11% 283
2021
Q4 		$1.96M Buy
53,023
+3,523
+7% +$144K 0.15% 240
2021
Q3 		$2.37M Buy
+49,500
New +$2.22M 0.17% 228
2016
Q2 		– Sell
-2,200
Closed -$58K – 445
2016
Q1 		$58K Hold
2,200
– – ﹤0.01% 555
2015
Q4 		$97K Buy
+2,200
New +$99.1K 0.01% 378

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

PDT Partners's ARCT Position: Q1 2025 in Review

PDT Partners sold out of Arcturus Therapeutics (ARCT) in Q1 2025, closing a stake of 90,298 shares — an estimated $1.53M sold.

PDT Partners first reported a position in ARCT in Q4 2015 and held it in 8 quarters. The position peaked at $2.37M in Q3 2021. 145 funds tracked by Wall St. Rank hold ARCT as of Q1 2025.

  • PDT Partners reported no remaining Arcturus Therapeutics position as of Q1 2025 after selling out during the quarter.
  • PDT Partners sold 90,298 Arcturus Therapeutics shares in Q1 2025, an estimated $1.53M.
  • PDT Partners first reported a position in Arcturus Therapeutics in Q4 2015 and held it in 8 quarters.
  • PDT Partners's Arcturus Therapeutics position peaked at $2.37M in Q3 2021.
  • 145 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2025.

Based on PDT Partners's 13F filing for Q1 2025, filed 15 May 2025.